Literature DB >> 17882603

Treatment of cannabis use disorders: a review of the literature.

Benjamin R Nordstrom1, Frances R Levin.   

Abstract

Cannabis is the most widely used illicit drug in the United States. Despite the fact that there are large numbers of people with cannabis dependence, relatively little attention has been paid to the treatment of this condition. This article seeks to critically review the existing literature about the various psychosocial and pharmacologic treatments of cannabis dependence. We begin with a discussion of the early treatment literature which draws primarily from anecdotal experience and open, uncontrolled trials and proceed through two recent, large, randomized controlled trials of psychotherapies for the treatment of cannabis dependence. We conclude that while a number of psychotherapies have been found to be effective in treating this disorder, with the exception of adding vouchers to reinforce negative urine toxicology screens, no form of psychotherapy has been found to be more effective than any other. In addition, we review the only two clinical pharmacotherapy trials for cannabis dependence as well as the pre-clinical laboratory pharmacotherapy trials in cannabis dependent individuals. We also review pertinent dual-diagnosis pharmacotherapy trials and discuss potential future directions in treatment research for the pharmacotherapy of cannabis dependence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882603     DOI: 10.1080/10550490701525665

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  47 in total

Review 1.  Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.

Authors:  Peng Yang; Lirong Wang; Xiang-Qun Xie
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 2.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 3.  Novel medications to treat addictive disorders.

Authors:  Iván D Montoya; Frank Vocci
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

Review 4.  An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions.

Authors:  Rebecca D Crean; Natania A Crane; Barbara J Mason
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

5.  Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities.

Authors:  Benedikt Fischer; Sameer Imtiaz; Katherine Rudzinski; Jürgen Rehm
Journal:  J Public Health (Oxf)       Date:  2015-01-28       Impact factor: 2.341

6.  A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Authors:  Barbara J Mason; Rebecca Crean; Vivian Goodell; John M Light; Susan Quello; Farhad Shadan; Kimberly Buffkins; Mark Kyle; Murali Adusumalli; Adnan Begovic; Santosh Rao
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

7.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

8.  Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese K Killeen; Amanda M Wagner; Kathleen T Brady; C Lindsay DeVane; Jessica Norton
Journal:  Drug Alcohol Depend       Date:  2015-08-25       Impact factor: 4.492

Review 9.  Cannabis use during pregnancy and postpartum.

Authors:  Sophia Badowski; Graeme Smith
Journal:  Can Fam Physician       Date:  2020-02       Impact factor: 3.275

10.  A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.

Authors:  Kenneth M Carpenter; David McDowell; Daniel J Brooks; Wendy Y Cheng; Frances R Levin
Journal:  Am J Addict       Date:  2009 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.